Vanda Pharmaceuticals (NASDAQ:VNDA) is a clinical-stage biopharmaceutical company focused on the development and commercialization of innovative therapies for central nervous system (CNS) disorders and rare diseases. The company’s research and development efforts center on sleep-wake regulation, mood disorders, and movement disorders. Vanda’s mission is to address unmet medical needs by advancing novel molecules through clinical trials and regulatory review.
Vanda’s flagship commercial product is Hetlioz (tasimelteon), a melatonin receptor agonist approved by the U.S. Food and Drug Administration (FDA) for the treatment of non-24-hour sleep-wake disorder in totally blind individuals and for night-time sleep disturbances in Smith–Magenis syndrome. The company also markets Firdapse (amifampridine), indicated for the treatment of Lambert–Eaton myasthenic syndrome. Both products exemplify Vanda’s expertise in rare and orphan diseases and reflect its ability to bring targeted therapies from concept to market.
Beyond its approved products, Vanda maintains a diversified clinical pipeline that includes VNP01 for the treatment of manic episodes in bipolar I or II disorder and other investigational compounds addressing depressive disorders, Parkinson’s disease, and additional CNS indications. The company leverages strategic partnerships and in-house expertise to advance these candidates through Phase II and III trials, with the goal of expanding its therapeutic portfolio and geographic reach.
Founded in 2003 and headquartered in Washington, D.C., Vanda Pharmaceuticals operates primarily in the United States and holds regulatory authorizations in Europe and other international markets. Since January 2014, Dr. Mihael Polymeropoulos has served as President and Chief Executive Officer, guiding the company through successful product launches and global expansion efforts. Vanda’s leadership team combines clinical, regulatory, and commercial experience to support its strategic growth in the CNS and rare disease arenas.
